CJC-1295 no DAC + Ipamorelin 10mg

CJC-1295 No DAC + Ipamorelin 10mg — Dual Growth Hormone Secretagogue Research Combination

CJC-1295 No DAC + Ipamorelin 10mg is a co-lyophilised research combination containing two structurally distinct growth hormone secretagogues: CJC-1295 without Drug Affinity Complex (also designated Modified GRF 1-29, or Mod-GRF 1-29), and Ipamorelin, a selective ghrelin receptor agonist. Each vial supplied by AbsoluteBioLab contains 5mg of CJC-1295 No DAC and 5mg of Ipamorelin, lyophilised together as a single research-grade preparation. Both peptides are verified by reverse-phase high-performance liquid chromatography (RP-HPLC) to a minimum purity of ≥99.0%, with identity confirmed by electrospray ionisation mass spectrometry (ESI-MS). This combination is used in pre-clinical and in vitro research contexts where investigators require simultaneous stimulation of the growth hormone-releasing hormone receptor (GHRHR) and the growth hormone secretagogue receptor 1a (GHSR-1a).

CJC-1295 No DAC is a 29-amino-acid analogue of endogenous growth hormone-releasing hormone (GHRH 1-44). The “No DAC” designation distinguishes it from CJC-1295 with Drug Affinity Complex (CJC-1295 DAC), which incorporates a lysine-maleimide linker enabling covalent albumin binding and a markedly extended plasma half-life. The No DAC variant lacks this modification, retaining a half-life profile closer to native GHRH whilst incorporating four amino acid substitutions — Ala2→D-Ala, Gln8→Ala, Ala15→Ala, Leu27→Leu — that confer resistance to dipeptidyl peptidase IV (DPP-IV) cleavage. Ipamorelin (Ala-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide ghrelin mimetic that selectively activates GHSR-1a with high receptor selectivity and minimal cross-reactivity at the ACTH, cortisol, or prolactin axes — a selectivity profile that distinguishes it from earlier ghrelin mimetics such as GHRP-2 and GHRP-6.^[1]

Compound Identity Matrix

Analytical Documentation and Quality Release Specification

Every batch of CJC-1295 No DAC + Ipamorelin 10mg undergoes a two-tier analytical release protocol before dispatch from AbsoluteBioLab. The primary purity assessment is performed by reverse-phase HPLC using a C18 stationary phase with UV detection at 220 nm; both peptide components are resolved and quantified independently within the co-lyophilised matrix. The minimum release specification for each component is ≥99.0% purity by area normalisation. Identity confirmation is provided by ESI-MS, with observed mass-to-charge ratios compared against theoretical values for CJC-1295 No DAC ([M+4H]⁴⁺ = 842.50 Da) and Ipamorelin ([M+H]⁺ = 712.88 Da). Endotoxin content is assessed by the Limulus Amebocyte Lysate (LAL) kinetic turbidimetric method and must be below 1.0 EU/mg for release. Residual moisture in the lyophilised cake is confirmed below 5.0% by Karl Fischer titration. Batch-specific Certificate of Analysis (CoA) documents are available through the AbsoluteBioLab CoA Portal and are included with each order.

Mechanism of Action — Dual-Receptor Growth Hormone Axis Stimulation

CJC-1295 No DAC: GHRHR Agonism

CJC-1295 No DAC binds to the growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor expressed on somatotroph cells of the anterior pituitary. Receptor engagement activates adenylyl cyclase via Gαs coupling, elevating intracellular cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). PKA phosphorylates the transcription factor CREB, which drives expression of the GH1 gene and promotes somatotroph proliferation. The net effect is a pulsatile release of growth hormone (GH) from the anterior pituitary that mirrors the physiological pattern of endogenous GHRH-driven secretion. The four amino acid substitutions in Mod-GRF 1-29 — most critically the Ala2→D-Ala substitution at the DPP-IV cleavage site — extend the functional half-life of the peptide in solution from approximately 2 minutes (native GHRH 1-29) to approximately 30 minutes, whilst preserving full GHRHR agonist activity.^[1]

Ipamorelin: Selective GHSR-1a Agonism

Ipamorelin acts at the growth hormone secretagogue receptor 1a (GHSR-1a), a constitutively active class A GPCR expressed in the anterior pituitary, hypothalamus, and peripheral tissues. GHSR-1a activation triggers Gαq/11-mediated phospholipase C (PLC) activation, generating inositol trisphosphate (IP3) and diacylglycerol (DAG), which mobilises intracellular calcium and activates protein kinase C (PKC). The resulting calcium transient in somatotroph cells is the proximate trigger for GH vesicle exocytosis. Ipamorelin’s selectivity profile is a defining research characteristic: unlike GHRP-2 and GHRP-6, which produce significant co-secretion of ACTH and cortisol at effective concentrations, Ipamorelin demonstrates minimal activity at the ACTH, cortisol, and prolactin axes in in vitro assays.^[2]

Convergent Dual-Receptor Stimulation in Research Models

The pharmacological rationale for combining CJC-1295 No DAC with Ipamorelin in research models is the convergent but mechanistically distinct stimulation of GH secretion via two independent receptor systems. GHRHR (activated by CJC-1295 No DAC) and GHSR-1a (activated by Ipamorelin) are co-expressed on somatotroph cells and their downstream signalling cascades — cAMP/PKA and IP3/DAG/PKC respectively — converge at the level of intracellular calcium mobilisation and GH vesicle exocytosis. In vitro studies using primary pituitary cell cultures and GH3 cell lines have examined co-stimulation of both receptors to characterise GH secretion kinetics under dual-pathway activation.^{[2] [3]} The extent to which this represents a synergistic interaction versus additive stimulation remains an active area of pre-clinical investigation; the combination evidence base is largely preclinical and the clinical evidence gap has been noted in recent reviews.^{[4] [5]}

Format Specification and Storage

Note: Reconstituted solution storage, solvent selection, working concentration, and stability period guidance are not provided, consistent with AbsoluteBioLab’s Research Use Only supply policy. Researchers should refer to their institutional SOPs and the published literature for handling reconstituted peptide solutions. Stability period is stated on the batch-specific CoA.

Research Applications

CJC-1295 No DAC + Ipamorelin is employed across a range of pre-clinical research applications focused on the growth hormone axis, somatotroph biology, and downstream IGF-1 signalling. The combination’s dual-receptor mechanism makes it a preferred tool compound for investigators studying GH pulse dynamics, somatotroph secretory capacity, and the interaction between GHRH and ghrelin signalling pathways in cell-based and ex vivo models.

• GH Pulse Amplitude Studies: In vitro models using primary pituitary cell cultures or GH3 cell lines to characterise GH secretion kinetics under dual GHRHR/GHSR-1a co-stimulation.
• Somatotroph Receptor Pharmacology: Radioligand binding displacement assays and functional cAMP/IP3 second messenger assays to characterise receptor occupancy and downstream signalling.
• IGF-1 Axis Research: Ex vivo hepatocyte models examining GH-stimulated IGF-1 production and JAK2/STAT5b signalling cascade activation.
• Metabolic Research: Adipocyte and skeletal muscle cell models investigating GH-mediated lipolysis, glucose uptake, and protein synthesis pathways.
• Comparative Secretagogue Studies: Head-to-head comparisons with GHRP-2, GHRP-6, Hexarelin, and CJC-1295 DAC to characterise selectivity, potency, and receptor desensitisation profiles.
• Neuropeptide Signalling Research: Hypothalamic neuron models examining GHSR-1a-mediated neuropeptide Y (NPY) co-release and orexigenic signalling.

Regulatory Status and Compliance

CJC-1295 No DAC (Modified GRF 1-29) and Ipamorelin are research compounds without approved medicinal product status in the United Kingdom, European Union, or United States. Neither compound is listed as a controlled substance under the UK Misuse of Drugs Act 1971 or the US Controlled Substances Act. Both peptides appear on the World Anti-Doping Agency (WADA) Prohibited List under Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) and are therefore prohibited in competitive sport. AbsoluteBioLab supplies these compounds exclusively for in vitro laboratory research to verified research institutions, universities, and qualified investigators. All orders are subject to our Terms of Service and Research Use Policy. Purchasers are responsible for ensuring compliance with all applicable national and institutional regulations governing the acquisition and use of research peptides.

Related Research Guides

References

1. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797. doi:10.1210/jc.2006-0184
2. Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552
3. Bowers CY. Unnatural growth hormone-releasing peptide begets natural ghrelin. J Clin Endocrinol Metab. 2001;86(4):1464–1469. doi:10.1210/jcem.86.4.7430
4. Dominikowski A, Rekos Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol. 2026. Consensus
5. Mayfield CK, Bolia IK, Feingold CL, et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med. 2026. Consensus